182 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
circulating miR-1, miR-133, miR-208, miR-499
I/C
O
diagnostic values in AMI
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
patients with cocaine-associated chest pain
I/C
cocaine use, low risk patients, mixed risk patients
O
acute myocardial infarction (AMI)
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
patients with M. chimaera infection and a prior history of cardiac surgery
I/C
surgical aortic valve replacement or combined aortic valve and root replacement, lethal events
O
better survival
P
patients with acute myocardial infarction and multivessel disease
I/C
FFR-guided PCI, angiography-guided PCI
O
increased QALYs, cost savings
P
acute mild ischemic stroke (AMIS)
I/C
dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, single antiplatelet therapy (SAPT) with only aspirin or clopidogrel
O
90-day Modified Rankin Scale (mRS) Score (MRS score 0-1), symptomatic intracranial hemorrhage (SICH), and 90-day mortality